Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication

Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacolo...

Descripción completa

Detalles Bibliográficos
Autores: Bellet, Meritxell, Ruiz, Ada, de la Peña, Lorena
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/44366
Acceso en línea:http://hdl.handle.net/10230/44366
http://dx.doi.org/10.1177/1758835919833867
Access Level:acceso abierto
Palabra clave:CDK inhibitors
Breast cancer
Palbociclib
Ribociclib
id ES_f40a599d9a920e7cd4e0af6fc056df00
oai_identifier_str oai:repositori.upf.edu:10230/44366
network_acronym_str ES
network_name_str España
repository_id_str
spelling Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medicationBellet, MeritxellRuiz, Adade la Peña, LorenaCDK inhibitorsBreast cancerPalbociclibRibociclibDrug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.SAGE Publications202020202019info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/44366http://dx.doi.org/10.1177/1758835919833867reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésCopyright © The Author(s), 2019. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).http://www.creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/443662026-06-12T07:21:37Z
dc.title.none.fl_str_mv Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
spellingShingle Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
Bellet, Meritxell
CDK inhibitors
Breast cancer
Palbociclib
Ribociclib
title_short Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title_full Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title_fullStr Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title_full_unstemmed Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
title_sort Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
dc.creator.none.fl_str_mv Bellet, Meritxell
Ruiz, Ada
de la Peña, Lorena
author Bellet, Meritxell
author_facet Bellet, Meritxell
Ruiz, Ada
de la Peña, Lorena
author_role author
author2 Ruiz, Ada
de la Peña, Lorena
author2_role author
author
dc.subject.none.fl_str_mv CDK inhibitors
Breast cancer
Palbociclib
Ribociclib
topic CDK inhibitors
Breast cancer
Palbociclib
Ribociclib
description Drug-drug interactions are of significant concern in clinical practice in oncology, particularly in patients receiving Cyclin-dependent kinase (CDK) 4/6 inhibitors, which are typically exposed to long-term regimens. This article presents the highlights from the 'First Workshop on Pharmacology and Management of CDK4/6 Inhibitors: Consensus about Concomitant Medications'. The article is structured into two modules. The educational module includes background information regarding drug metabolism, corrected QT (QTc) interval abnormalities, management of psychotropic drugs and a comprehensive review of selected adverse effects of palbociclib and ribociclib. The collaborative module presents the conclusions of the five working groups, each of which comprised five experts from different fields. From these conclusions positive lists of drugs for treating common comorbid conditions that can be safely administered concomitantly with palbociclib and/or ribociclib were developed.
publishDate 2019
dc.date.none.fl_str_mv 2019
2020
2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/44366
http://dx.doi.org/10.1177/1758835919833867
url http://hdl.handle.net/10230/44366
http://dx.doi.org/10.1177/1758835919833867
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv http://www.creativecommons.org/licenses/by-nc/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://www.creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv SAGE Publications
publisher.none.fl_str_mv SAGE Publications
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869424434619613184
score 15,812429

Similares en LA Referencia